MET

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

81.230

Open

81.150

VWAP

80.90

Vol

152.25K

Mkt Cap

54.48B

Low

80.260

Amount

12.32M

EV/EBITDA(TTM)

9.97

Total Shares

711.12M

70.20B

EV/OCF(TTM)

4.25

P/S(TTM)

0.77

MetLife, Inc. is a financial services company. The Company is engaged in providing insurance, annuities, employee benefits and asset management for individual and institutional customers. The Company operates through six segments: Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its Group Benefits segment offers life insurance, dental, group short- and long-term disability, individual disability, accidental death and dismemberment (AD&D) insurance, vision, and accident and health insurance, as well as prepaid legal plans and pet insurance. It also sells administrative services-only (ASO) arrangements to some employers. Its RIS segment provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

18.35B

-1.79%

2.332

+2.28%

18.53B

+5.2%

2.393

+22.73%

18.88B

-4.34%

2.436

+16.56%

Estimates Revision

The market is revising Downward the revenue expectations for MetLife, Inc. (MET) for FY2025, with the revenue forecasts being adjusted by -0.54% over the past three months. During the same period, the stock price has changed by -1.54%.

Revenue Estimates for FY2025

Revise Downward

-0.54%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.53%

In Past 3 Month

Stock Price

Go Down

-1.54%

In Past 3 Month

11 Analyst Rating

15.50% Upside

Wall Street analysts forecast MET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MET is 92.91 USD with a low forecast of 86.00 USD and a high forecast of 98.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

15.50% Upside

Current: 80.440

Low

86.00

Averages

92.91

High

98.00

15.50% Upside

Current: 80.440

Low

86.00

Averages

92.91

High

98.00

Barclays

Alex Scott

Buy

Maintains

$95 → $88

2025-04-11

Reason

Barclays

Alex Scott

Price Target

$95 → $88

2025-04-11

Maintains

Buy

Reason

Barclays lowered the firm's price target on MetLife to $88 from $95 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for the insurance group. With life earnings facing challenges Barclays favors group benefits, excess capital, and "cheap" cash flows, the analyst tells investors in a research note. The firm says the sector is "navigating uncertainty."

Morgan Stanley

Nigel Dally

Buy

Maintains

$109 → $94

2025-04-10

Reason

Morgan Stanley

Nigel Dally

Price Target

$109 → $94

2025-04-10

Maintains

Buy

Reason

Morgan Stanley lowered the firm's price target on MetLife to $94 from $109 and keeps an Overweight rating on the shares. On average across the firm's life insurance coverage, Q1 EPS estimates declined 3% from prior estimates and its 2025 EPS estimates declined 4% from prior estimates, though results vary across companies, notes the analyst in a preview for the group. For underwriting-oriented companies that should not be as sensitive to equity market fluctuations, the firm's estimates generally did not change as much, but it still moved underwriter estimates down as they likely face an incrementally more challenging operating environment, the analyst noted.

Wells Fargo

Elyse Greenspan

Buy

Maintains

$97 → $91

2025-04-10

Reason

Wells Fargo

Elyse Greenspan

Price Target

$97 → $91

2025-04-10

Maintains

Buy

Reason

Wells Fargo lowered the firm's price target on MetLife to $91 from $97 and keeps an Overweight rating on the shares. The firm notes that the quarter lost a little luster with the tariff backdrop and Wells thinks a bigger focus will be on any views of tariffs/ensuring macro backdrop.

Keefe, Bruyette & Woods

Ryan Krueger

Buy

Maintains

$98 → $95

2025-04-09

Reason

Keefe, Bruyette & Woods

Ryan Krueger

Price Target

$98 → $95

2025-04-09

Maintains

Buy

Reason

Keefe Bruyette analyst Ryan Krueger lowered the firm's price target on MetLife to $95 from $98 and keeps an Outperform rating on the shares.

JP Morgan

Jimmy Bhullar

Buy

Maintains

$88 → $86

2025-04-02

Reason

JP Morgan

Jimmy Bhullar

Price Target

$88 → $86

2025-04-02

Maintains

Buy

Reason

JPMorgan lowered the firm's price target on MetLife to $86 from $88 and keeps an Overweight rating on the shares. The firm shifted its view on life insurance stocks from Positive to Neutral, saying risk/rewards "have become less compelling given an incrementally downbeat outlook for business fundamentals." It forecasts life insurers will report "weak" earnings and mixed business trends in Q1. JPMorgan reduced estimates as part of a Q1 earnings preview.

Piper Sandler

John Barnidge

Buy

Maintains

$92 → $94

2025-04-02

Reason

Piper Sandler

John Barnidge

Price Target

$92 → $94

2025-04-02

Maintains

Buy

Reason

Piper Sandler analyst John Barnidge raised the firm's price target on MetLife to $94 from $92 and keeps an Overweight rating on the shares. The firm is generally reducing EPS estimates for the group driven by fee and spread headwinds, and favors underwriting areas of lifecoland as a result. Fee businesses have client outflows, less fee and trading days and seasonally higher expenses. Spread has prospect of variable investment income normalization being pushed out, floater impact and possible negative commentary around prospective spread income expectations in Piper's opinion.

See All Ratings

Valuation Metrics

The current forward P/E ratio for MetLife Inc (MET.N) is 8.55, compared to its 5-year average forward P/E of 8.23. For a more detailed relative valuation and DCF analysis to assess MetLife Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

8.23

Current PE

8.55

Overvalued PE

9.43

Undervalued PE

7.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.77

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

9.69

Undervalued EV/EBITDA

-2.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

0.71

Current PS

0.70

Overvalued PS

0.80

Undervalued PS

0.62